Potassium chloride 6% (potassium 16mmol/20ml) / Magnesium chloride 16.3% (magnesium 16mmol/20ml) / Procaine hydrochloride 280mg solution for cardioplegia 20ml ampoules
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Potassium chloride + Magnesium chloride + Procaine
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Potassium chloride + Magnesium chloride + Procaine on the MHRA register
Sterile Concentrate for Cardioplegia Infusion 20ml ampoules
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 12 studies.
1985–2025
Showing all 12 studies, sorted by most relevant.
Kashinath R. Patil, Atri D. Tripathi, Gopal Pathak, et al.
Journal of Chemical & Engineering Data, 1991
J. Lorenzo, R. Bermúdez, R. Domínguez, et al.
Food Control, 2015
J. Gates, R. Wood
Journal of Chemical & Engineering Data, 1985
Danqian Wang, Y. Yue, Zhichao Xie, et al.
Corrosion Science, 2022
Shujie Yang, Xiaoli Ma, Yanfeng Huang, et al.
Foods, 2024
The search for alternative salt formulations similar to sodium chloride and their effect on marinated meat products is of great significance to the low-sodium meat processing industry. The main purpose of this study was to investigate the effect of partially replacing sodium chloride with potassium lactate, calcium ascorbate, and magnesium chloride on the sodium content, water activity and distribution, protein solubility, microstructure, sensory characteristics and volatile flavor compounds in low-sodium marinated beef. The sodium content in the test group decreased up to 28% compared to 100% in the sodium chloride group C1. The formulation including 60% sodium chloride and a total of 40% compound alternative salts in groups F1 and F2 increased their myofibril fragmentation index and promoted the disruption of the myogenic fiber structure. Group F1 (the ratio of potassium lactate, calcium ascorbate and magnesium chloride was 2:1:1) performed higher solubility of myofibrillar proteins and lower transverse relaxation value than group F2 detected by low-field nuclear magnetic resonance, which indicated that F1 formulation was beneficial to promote the solubility of myofibrillar proteins and attenuate the water mobility of marinated beef. Moreover, group F1 had a more similar microstructure and more similar overall sensory attributes to group C1 according to the scanning electron microscopy. The sensory evaluation showed higher peak intensity and response values of volatile flavor compounds than group C1 and C2 (only 60% sodium chloride) when detected using gas chromatography-ion mobility spectrometry technology, which indicated that the compound alternative salts of group F1 can improve the lower quality of low-sodium marinated beef and perform similar attributes to the C1 sample regarding moisture distribution and microstructure and even performs better than it with regards to flavor. Therefore, the F1 formula possessed greater potential for application in low-sodium marinated meat products.
Abstract licence: CC BY
K. Manimekalai, P. Jayaprakash, N. Padmamalini, et al.
Journal of Materials Science: Materials in Electronics, 2023
Wenting Cheng, Qianqian Li, Ying Zhai, et al.
Chinese Journal of Chemical Engineering, 2025
W. Vongpatanasin, John M. Giacona, Danielle Pittman, et al.
Hypertension (Dallas, Tex. : 1979), 2023
- Antihypertensive Agents
- Blood Glucose
- Blood Pressure
Elmeligy E, Abdel-Lah ES, Almuhanna AH, et al.
2025
Introduction: Acute ruminal impaction is a metabolic disorder of the digestive system that happens in ruminants that have been fed a high amount of cereal grains, negatively impacting animal health and productivity. The present study clarified the diagnostic and prognostic significance of certain clinico-biochemical findings in evaluation of the efficacy of the applied therapeutic regimen in sheep with acute carbohydrate engorgement. This was conducted through monitoring changes in clinical findings, blood pictures, ruminal function biomarkers, serum hepatorenal indicators, and serum electrolytes indices in fattening Osimi sheep on days 0 pre-therapy and days 3, 7, 15, 30, 60, and 90 post-therapy. Methods: = 100) with acute ruminal impaction. They were exposed to a 5-day integrated treatment regimen. It included IV infusion of sodium bicarbonate and glucose, an oral drenching of each of magnesium hydroxide, antibloat preparation (Bloatryal), and laxative powder (Apilax Powder). This was followed by injectable doses of flunixin meglumine, diphenhydramine HCl, clanobutin sodium, broad spectrum antibiotic (Combikel 20 + 20), and doramectin (a broad-spectrum anthelmintic). The investigated sheep had a full clinical examination and hemato-biochemical tests from day 0 (pre-therapy) up to day's 3-90 post-therapy. Results and conclusion: The applied therapeutic regimen (1-5 days' therapeutic program) was highly effective in cases of acute ruminal impaction in sheep, as evidenced by a clear improvement in their clinical health status (up to 15 days post-therapy) as well as restoring their reference intervals of ruminal functions biomarkers, blood picture indices, and hepatorenal functions throughout the current study (15-60 days post-therapy). Except for hepatorenal functions, all estimated laboratory indices restored their physiological intervals on the 15th day post-therapy. A 30- to 60-day follow-up period was required post-therapy until hepatorenal function restored their physiological reference intervals.
Abstract licence: CC BY
Suzana Jahić, Sebila Rekanovic, Samira Hotić, et al.
Technologica acta, 2024
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.